Science-led regulatory strategies in nonclinical development of new medicines

被引:1
|
作者
Roberts, Ruth [1 ]
Jones, David [1 ]
机构
[1] ApconiX, Alderley Pk, Macclesfield SK10 4TG, England
关键词
Drug Discovery; Drug Development; Regulatory Guidelines; Decision making;
D O I
10.1093/toxres/tfad017
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
The development of a pharmaceutical is a stepwise process involving an evaluation of both animal and human efficacy and safety information. Regulations around drug development exist to protect people and the environment from harm and should create a level playing field for business, allowing well-run companies to thrive. However, adherence to good science should guide decisions rather than rigorously following guidelines, and there is almost always more than one way to get to the ultimate goal.
引用
收藏
页码:145 / 149
页数:5
相关论文
共 50 条
  • [41] Bridging the gap between science-led research and evaluation of clinical practice: the role of service innovation audits and case studies
    McAuliffe, Shane
    Unwin, David
    Bradfield, James
    Ray, Sumantra
    Martyn, Kathy
    BMJ NUTRITION, PREVENTION & HEALTH, 2021, 4 (01) : 350 - 351
  • [42] Streamlining nonclinical drug development using the FDA 505(b)(2) new drug application regulatory pathway
    Salminen, William F.
    Wiles, Marc E.
    Stevens, Ruth E.
    DRUG DISCOVERY TODAY, 2019, 24 (01) : 46 - 56
  • [43] Editorial: Drug development of herbal medicines: Regulatory perspectives
    Bilia, Anna Rita
    Mukherjee, Pulok Kumar
    Andrade-Cetto, Adolfo
    Katiyar, Chandra Kant
    Bachar, Sitesh C. C.
    Matsabisa, Motlalepula Gilbert
    Mandal, Subhash C. C.
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [44] RESEARCH AND DEVELOPMENT OF NEW MEDICINES
    ANKIER, SI
    WARRINGTON, SJ
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 1989, 17 (05) : 407 - 416
  • [45] New strategies for polymer development in pharmaceutical science - a short review
    Godwin, A
    Bolina, K
    Clochard, M
    Dinand, E
    Rankin, S
    Simic, S
    Brocchini, S
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2001, 53 (09) : 1175 - 1184
  • [46] Incorporating New Approach Methodologies into Regulatory Nonclinical Pharmaceutical Safety Assessment
    Turner, Jan
    Pound, Pandora
    Owen, Carla
    Hutchinson, Isobel
    Hop, Marina
    Chau, David Y. S.
    Silva, Lady V. Barrios
    Coleman, Mike
    Dubourg, Audrey
    Harries, Lorna W.
    Hutter, Victoria
    Kenna, J. Gerry
    Lauschke, Volker M.
    Neuhaus, Winfried
    Roper, Clive
    Watkins, Paul B.
    Welch, Jonathan
    Alvarez, Laura Rego
    Taylor, Katy
    ALTEX-ALTERNATIVES TO ANIMAL EXPERIMENTATION, 2023, 40 (03) : 519 - 532
  • [47] Regulatory science plays an important role in the global development of new drugs
    Tohkin, Masahiro
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2015, 128 (03) : S15 - S15
  • [48] Regulatory science for new drug development and pharmacological research: Industry perspective
    Kobayashi, Kazumichi
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2015, 128 (03) : S14 - S14
  • [49] Nonclinical Safety Assessment of Anti-Factor D: Key Strategies and Challenges for the Nonclinical Development of Intravitreal Biologics
    Bantseev, Vladimir
    Erickson, Rebecca
    Leipold, Douglas
    Amaya, Caroline
    Miller, Paul E.
    Booler, Helen
    Thackaberry, Evan A.
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2018, 34 (1-2) : 204 - 213
  • [50] CONSIDERATIONS REGARDING THE DEVELOPMENT OF INDIVIDUAL NONCLINICAL TEST STRATEGIES IN THE EUROPEAN COMMUNITY
    GUNZEL, P
    BASS, R
    HUMAN & EXPERIMENTAL TOXICOLOGY, 1991, 10 (05): : 297 - 304